Journal
JOURNAL OF MEDICAL VIROLOGY
Volume 94, Issue 1, Pages 388-392Publisher
WILEY
DOI: 10.1002/jmv.27287
Keywords
COVID-19; ELISA; microneutralization; SARS-CoV-2
Categories
Funding
- EUROIMMUM Medizinische Labordiagnostika AG
Ask authors/readers for more resources
This study analyzed the correlation between binding IgG and neutralizing antibodies in COVID-19 patients, revealing a strong positive relationship and supporting the use of QuantiVac ELISA to assess protective immunity post-infection or vaccination.
In the current COVID-19 pandemic, a better understanding of the relationship between merely binding and functionally neutralizing antibodies is necessary to characterize protective antiviral immunity following infection or vaccination. This study analyzes the level of correlation between the novel quantitative EUROIMMUN Anti-SARS-CoV-2 QuantiVac ELISA (IgG) and a microneutralization assay. A panel of 123 plasma samples from a COVID-19 outbreak study population, preselected by semiquantitative anti-SARS-CoV-2 IgG testing, was used to assess the relationship between the novel quantitative ELISA (IgG) and a microneutralization assay. Binding IgG targeting the S1 antigen was detected in 106 (86.2%) samples using the QuantiVac ELISA, while 89 (72.4%) samples showed neutralizing antibody activity. Spearman's correlation analysis demonstrated a strong positive relationship between anti-S1 IgG levels and neutralizing antibody titers (r(s )= 0.819, p < 0.0001). High and low anti-S1 IgG levels were associated with a positive predictive value of 72.0% for high-titer neutralizing antibodies and a negative predictive value of 90.8% for low-titer neutralizing antibodies, respectively. These results substantiate the implementation of the QuantiVac ELISA to assess protective immunity following infection or vaccination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available